Alkem Laboratories Launches India’s First Semaglutide Single-Shot Pre-Filled Syringes; Prices Start at ₹350

Alkem Laboratories has announced the launch of semaglutide in single-shot pre-filled syringes, becoming the first company in India to introduce the drug in this format. The product is available in multiple dose strengths with prices starting at ₹350, aiming to improve accessibility and convenience for patients managing Type 2 diabetes mellitus and obesity.

Alkem Expands Semaglutide Portfolio with New Syringe Format 

Alkem Laboratories has expanded its semaglutide portfolio with the introduction of single-shot pre-filled syringes. The company stated that the ready-to-use format offers enhanced convenience while lowering entry barriers to semaglutide treatment through affordable pricing. 

The launch marks another step in Alkem’s efforts to broaden treatment options for patients suffering from metabolic disorders. 

DCGI Approval for Semaglutide Pre-Filled Syringes

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity, to be used alongside diet and exercise. 

With this approval, Alkem becomes the first company in India to offer semaglutide in the single-shot pre-filled syringe format, providing patients and healthcare professionals with an additional drug delivery option. 

Expanding Semaglutide Delivery Formats 

In March 2026, Alkem had launched semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market. The company has also secured regulatory approval for semaglutide vials, which are expected to be launched in the near future. 

The addition of pre-filled syringes further expands the range of semaglutide delivery formats available through Alkem, allowing patients and doctors greater flexibility in selecting treatment options. 

Management Commentary 

Commenting on the development, Dr. Vikas Gupta, Chief Executive Officer of Alkem, said that semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy. 

Read More: Alkem Laboratories Share Price in Focus; Increases Investment to ₹1,036 Crore for Ujjain Facility 

Alkem Laboratories Share Price Performance 

On June 2, 2026, Alkem Laboratories share price closed at ₹5,246.95, down 1.32% on the BSE from the previous close. The company’s current market capitalisation stood at ₹62,735.16 crore. 

Conclusion 

With the launch of India’s first semaglutide single-shot pre-filled syringes, Alkem Laboratories has strengthened its presence in the metabolic care segment. Affordable pricing and expanded delivery options are expected to improve access to semaglutide-based treatment for patients managing Type 2 diabetes and obesity. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.   

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.